Cargando…

Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain

We summarize efficacy and safety findings from 4 double-blind, placebo-controlled, 12-week studies and 1 open-label, uncontrolled, 34-week maintenance-of-effect (MOE) study that examine duloxetine 40 and 60 mg once daily (QD) in patients with diabetic peripheral neuropathic pain (DPNP). In all place...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skljarevski, Vladimir, Frakes, Elijah P., Sagman, Doron, Lipsius, Sarah, Heinloth, Alexandra N., Dueñas Tentori, Héctor J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437646/ https://www.ncbi.nlm.nih.gov/pubmed/22973509 http://dx.doi.org/10.1155/2012/898347

Ejemplares similares

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study
por: Yasuda, Hitoshi, et al.
Publicado: (2015)

Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo
por: Gao, Y, et al.
Publicado: (2015)

Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients
por: Lipkovich, Ilya A, et al.
Publicado: (2014)

Duloxetine in the management of diabetic peripheral neuropathic pain
por: Ormseth, Michelle J, et al.
Publicado: (2011)

Review of duloxetine in the management of diabetic peripheral neuropathic pain
por: Smith, Timothy, et al.
Publicado: (2007)

Clinical meaningfulness of duloxetine’s effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial
por: Yue, Li, et al.
Publicado: (2019)

Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
por: Zilliox, Lindsay, et al.
Publicado: (2010)

Efficacy of Duloxetine in Patients with Chronic Pain Conditions
por: Skljarevski, Vladimir, et al.
Publicado: (2011)

Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data
por: Wang, Guochun, et al.
Publicado: (2019)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
por: White, Darrell, et al.
Publicado: (2023)

Duloxetine use in chronic painful conditions – individual patient data responder analysis
por: Moore, RA, et al.
Publicado: (2014)

Attributes of response in depressed patients switched to treatment with duloxetine
por: Sagman, D, et al.
Publicado: (2011)

A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain
por: King, Jordan B, et al.
Publicado: (2015)

Duloxetine and pregabalin in neuropathic pain of lung cancer patients
por: Gül, Şule Karabulut, et al.
Publicado: (2020)

Long‐term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified‐release capsules once daily
por: Del Rosso, James Q., et al.
Publicado: (2021)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain
por: Quilici, Sibilia, et al.
Publicado: (2009)

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials
por: Alev, Levent, et al.
Publicado: (2017)

Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis
por: Jiang, Lanying, et al.
Publicado: (2022)

Effect of duloxetine on neuropathic pain in patients intolerant to continuous administration of pregabalin
por: Shimada, Yohei, et al.
Publicado: (2017)

A Prospective Observational Study Comparing the Efficacy and Safety of Duloxetine and Pregabalin in Diabetic Peripheral Neuropathic Pain
por: Shah, Islam, et al.
Publicado: (2022)

Observational study of upper gastrointestinal tract bleeding events in patients taking duloxetine and nonsteroidal anti-inflammatory drugs: a case-control analysis
por: Li, Hu, et al.
Publicado: (2014)

The efficacy of duloxetine depends on spinal cholinergic plasticity in neuropathic pain model rats
por: Kato, Daiki, et al.
Publicado: (2022)

Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris
por: Pozdnyakov, Yuri M.
Publicado: (2018)

Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin
por: Enomoto, Hiroyuki, et al.
Publicado: (2018)

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review
por: Plested, Melanie, et al.
Publicado: (2010)

Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents
por: Kim, Woojin, et al.
Publicado: (2017)

Effectiveness of Duloxetine for Postsurgical Chronic Neuropathic Disorders after Spine and Spinal Cord Surgery
por: Tsuji, Osahiio, et al.
Publicado: (2021)

Rosuvastatin Synergistically Enhances the Antinociceptive Efficacy of Duloxetine in Paclitaxel-Induced Neuropathic Pain in Mice
por: Lobos, Nicolás, et al.
Publicado: (2023)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study
por: Won, Ji Eon, et al.
Publicado: (2018)

The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports
por: Perahia, David G, et al.
Publicado: (2013)

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
por: Roehrborn, Claus G, et al.
Publicado: (2008)

Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome
por: Benelli, Andrea, et al.
Publicado: (2018)

Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial
por: Zaazaa, Adham, et al.
Publicado: (2023)

Duloxetine Inhibits Microglial P2X4 Receptor Function and Alleviates Neuropathic Pain after Peripheral Nerve Injury
por: Yamashita, Tomohiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6jp72iumrb1r0dt19h1kirplk2